Randomized phase HI trial of (131)iodine-tositumomab (bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) vs. rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): No difference in progression-free (PFS) or overall survival (OS) Meeting Abstract
| Authors: | Vose, J. M.; Carter, S. L.; Burns, L. J.; Ayala, E.; Press, O. W.; Moskowitz, C. H.; Stadtmauer, E. A.; Mineishi, S.; Ambinder, R. F.; Fenske, T. S.; Horowitz, M. M.; Tomblyn, M. |
| Abstract Title: | Randomized phase HI trial of (131)iodine-tositumomab (bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) vs. rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): No difference in progression-free (PFS) or overall survival (OS) |
| Meeting Title: | 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis |
| Journal Title: | Blood |
| Volume: | 118 |
| Issue: | 21 |
| Meeting Dates: | 2011 Dec 10-13 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2011-11-01 |
| Start Page: | 303 |
| Language: | English |
| ACCESSION: | WOS:000299597100662 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V118.21.661.661 |
| Notes: | --- - Meeting Abstract: 661 - 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis - DEC 10-13, 2011 - San Diego, CA - "Source: Wos" |
